Literature DB >> 30592483

Association of Parenteral Anticoagulation Therapy With Outcomes in Chinese Patients Undergoing Percutaneous Coronary Intervention for Non-ST-Segment Elevation Acute Coronary Syndrome.

Ji-Yan Chen1, Peng-Cheng He1,2, Yuan-Hui Liu1, Xue-Biao Wei1, Lei Jiang1, Wei Guo1, Chong-Yang Duan3, Yan-Song Guo4, Xiao-Ping Yu5, Jun Li6, Wen-Sheng Li7, Ying-Ling Zhou1, Chun-Ying Lin1,2, Jian-Fang Luo1, Dan-Qing Yu1, Zhu-Jun Chen1, Wei Chen4, Yi-Yue Chen5, Zhi-Qiang Guo2, Qing-Shan Geng1, Ning Tan1.   

Abstract

Importance: The association of parenteral anticoagulation therapy with improved outcomes in patients with non-ST-segment elevation acute coronary syndrome was previously established. This benefit has not been evaluated in the era of dual antiplatelet therapy and percutaneous coronary intervention. Objective: To evaluate the association between parenteral anticoagulation therapy and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. Design, Setting, and Participants: This cohort study included 8197 adults who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome from January 1, 2010, to December 31, 2014, at 5 medical centers in China. Patients receiving parenteral anticoagulation therapy only after percutaneous coronary intervention were excluded. Exposures: Parenteral anticoagulation therapy. Main Outcomes and Measures: The primary outcome was in-hospital all-cause death and in-hospital major bleeding as defined by the Bleeding Academic Research Consortium definition (grades 3-5).
Results: Of 6804 patients who met the final criteria, 5104 (75.0%) were male, with a mean (SD) age of 64.2 (10.4) years. The incidence of in-hospital death was not significantly different between the patients who received and did not receive parenteral anticoagulation therapy (0.3% vs 0.1%; P = .13) (adjusted odds ratio, 1.27; 95% CI, 0.38-4.27; P = .70). A similar result was found for myocardial infarction (0.3% vs 0.3%; P = .82) (adjusted odds ratio, 0.77; 95% CI, 0.29-2.07; P = .61). In-hospital major bleeding was more frequent in the parenteral anticoagulation group (2.5% vs 1.0%; P < .001) (adjusted odds ratio, 1.94; 95% CI, 1.24-3.03; P = .004). At a median (interquartile range) follow-up of 2.96 years (1.93-4.46 years), all-cause death was not significantly different between the 2 groups (adjusted hazards ratio, 0.87; 95% CI, 0.71-1.07; P = .19), but the incidence of major bleeding was higher in the parenteral anticoagulation group (adjusted hazards ratio, 1.43; 95% CI, 1.01-2.02; P = .04). The propensity score analysis confirmed these primary analyses. Conclusions and Relevance: In the patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome, parenteral anticoagulation therapy was not associated with a lower risk of all-cause death or myocardial infarction but was significantly associated with a higher risk of major bleeding. These findings raise important safety questions about the current practice of routine parenteral anticoagulation therapy while we await randomized trials of this practice.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30592483      PMCID: PMC6439659          DOI: 10.1001/jamainternmed.2018.5953

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


  31 in total

1.  Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.

Authors:  Roxana Mehran; Sunil V Rao; Deepak L Bhatt; C Michael Gibson; Adriano Caixeta; John Eikelboom; Sanjay Kaul; Stephen D Wiviott; Venu Menon; Eugenia Nikolsky; Victor Serebruany; Marco Valgimigli; Pascal Vranckx; David Taggart; Joseph F Sabik; Donald E Cutlip; Mitchell W Krucoff; E Magnus Ohman; Philippe Gabriel Steg; Harvey White
Journal:  Circulation       Date:  2011-06-14       Impact factor: 29.690

Review 2.  Drug-eluting coronary-artery stents.

Authors:  Giulio G Stefanini; David R Holmes
Journal:  N Engl J Med       Date:  2013-01-17       Impact factor: 91.245

3.  2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Ezra A Amsterdam; Nanette K Wenger; Ralph G Brindis; Donald E Casey; Theodore G Ganiats; David R Holmes; Allan S Jaffe; Hani Jneid; Rosemary F Kelly; Michael C Kontos; Glenn N Levine; Philip R Liebson; Debabrata Mukherjee; Eric D Peterson; Marc S Sabatine; Richard W Smalling; Susan J Zieman
Journal:  J Am Coll Cardiol       Date:  2014-09-23       Impact factor: 24.094

4.  Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.

Authors:  C P Cannon; W S Weintraub; L A Demopoulos; R Vicari; M J Frey; N Lakkis; F J Neumann; D H Robertson; P T DeLucca; P M DiBattiste; C M Gibson; E Braunwald
Journal:  N Engl J Med       Date:  2001-06-21       Impact factor: 91.245

5.  Aspirin, heparin, or both to treat acute unstable angina.

Authors:  P Théroux; H Ouimet; J McCans; J G Latour; P Joly; G Lévy; E Pelletier; M Juneau; J Stasiak; P deGuise
Journal:  N Engl J Med       Date:  1988-10-27       Impact factor: 91.245

6.  Invasive Management Strategies and Antithrombotic Treatments in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome in China: Findings From the Improving CCC Project (Care for Cardiovascular Disease in China).

Authors:  Qing Yang; Ying Wang; Jing Liu; Jun Liu; Yongchen Hao; Sidney C Smith; Yong Huo; Gregg C Fonarow; Changsheng Ma; Junbo Ge; Kathryn A Taubert; Louise Morgan; Yang Guo; Wei Wang; Yujie Zhou; Dong Zhao
Journal:  Circ Cardiovasc Interv       Date:  2017-06       Impact factor: 6.546

7.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

Authors:  Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

8.  Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.

Authors:  M Cohen; P C Adams; G Parry; J Xiong; D Chamberlain; I Wieczorek; K A Fox; J H Chesebro; J Strain; C Keller
Journal:  Circulation       Date:  1994-01       Impact factor: 29.690

9.  2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on clinical data standards (writing committee to develop acute coronary syndromes and coronary artery disease clinical data standards).

Authors:  Christopher P Cannon; Ralph G Brindis; Bernard R Chaitman; David J Cohen; J Thomas Cross; Joseph P Drozda; Francis M Fesmire; Dan J Fintel; Gregg C Fonarow; Keith A Fox; Darryl T Gray; Robert A Harrington; Karen A Hicks; Judd E Hollander; Harlan Krumholz; Darwin R Labarthe; Janet B Long; Alice M Mascette; Connie Meyer; Eric D Peterson; Martha J Radford; Matthew T Roe; James B Richmann; Harry P Selker; David M Shahian; Richard E Shaw; Sharon Sprenger; Robert Swor; James A Underberg; Frans Van de Werf; Bonnie H Weiner; William S Weintraub
Journal:  J Am Coll Cardiol       Date:  2013-01-28       Impact factor: 24.094

Review 10.  Heparin versus placebo for non-ST elevation acute coronary syndromes.

Authors:  Carlos A Andrade-Castellanos; Luis E Colunga-Lozano; Netzahualpilli Delgado-Figueroa; Kirk Magee
Journal:  Cochrane Database Syst Rev       Date:  2014-06-27
View more
  12 in total

1.  Errors in the Figure 1 Caption, Table 1, and Supplement.

Authors: 
Journal:  JAMA Intern Med       Date:  2019-02-01       Impact factor: 21.873

2.  [Prehospital management of acute coronary syndrome in patients on long-term direct oral anticoagulant treatment].

Authors:  E Schneck; F K Schneck; J S Wolter; C W Hamm; V Mann; H Hauch; B Kemkes-Matthes; J T Gräsner; H V Groesdonk; D Dirkmann; M Sander; C Koch; F Brenck
Journal:  Anaesthesist       Date:  2019-12-04       Impact factor: 1.041

Review 3.  [Comments on the German consensus statement on prehospital treatment of acute coronary syndrome in patients under long-term treatment with novel oral anticoagulants (NOAC)].

Authors:  Emmanuel Schneck; Christian W Hamm; Franziska Schneck; Jan Sebastian Wolter; Daniel Dirkmann; Christian Koch; Michael Sander
Journal:  Anaesthesist       Date:  2021-03-24       Impact factor: 1.041

4.  Prognostic of different glomerular filtration rate formulas in patients receiving percutaneous coronary intervention: insights from a multicenter observational cohort.

Authors:  Wei Chen; Pengyuan Chen; Zhonghan Ni; Yuanhui Liu; Wei Guo; Lei Jiang; Xuebiao Wei; Jiyan Chen; Ning Tan; Pengcheng He; Yansong Guo
Journal:  BMC Cardiovasc Disord       Date:  2020-07-18       Impact factor: 2.298

5.  Periprocedural anticoagulation in non-ST-segment elevation acute coronary syndrome: time to reassess?

Authors:  Rishi Chandiramani; Davide Cao; Roxana Mehran
Journal:  Ann Transl Med       Date:  2020-04

6.  The association of baseline N-terminal pro-B-type natriuretic peptide with short and long-term prognosis following percutaneous coronary intervention in non-ST segment elevation acute coronary syndrome with multivessel coronary artery disease: a retrospective cohort study.

Authors:  Wen-Fei He; Lei Jiang; Yi-Yue Chen; Yuan-Hui Liu; Peng-Yuan Chen; Chong-Yang Duan; Li-Huan Zeng; Hua-Lin Fan; Xue-Biao Wei; Wei Guo; Wei Chen; Jun Li; Wen-Sheng Li; Zhi-Qiang Guo; Zhi-Kai Liu; Ning Tan; Ji-Yan Chen; Peng-Cheng He
Journal:  BMC Cardiovasc Disord       Date:  2021-04-21       Impact factor: 2.298

7.  Comparison of Prognostic Value Among 4 Risk Scores in Patients with Acute Coronary Syndrome: Findings from the Improving Care for Cardiovascular Disease in China-ACS (CCC-ACS) Project.

Authors:  Jieleng Huang; Xuebiao Wei; Yu Wang; Mei Jiang; Yingwen Lin; Zedazhong Su; Peng Ran; Yingling Zhou; Jiyan Chen; Danqing Yu
Journal:  Med Sci Monit       Date:  2021-03-01

8.  Trends in Bleeding Events Among Patients With Acute Coronary Syndrome in China, 2015 to 2019: Insights From the CCC-ACS Project.

Authors:  Xiao Wang; Guanqi Zhao; Mengge Zhou; Changsheng Ma; Junbo Ge; Yong Huo; Sidney C Smith; Gregg C Fonarow; Yongchen Hao; Jun Liu; Louise Morgan; Wei Gong; Yan Yan; Jing Liu; Dong Zhao; Yaling Han; Shaoping Nie
Journal:  Front Cardiovasc Med       Date:  2021-12-13

9.  The monocyte to high-density lipoprotein cholesterol ratio and outcomes in type 2 diabetes mellitus patients with non-ST-segment elevation acute coronary syndrome.

Authors:  Chen Li; Hualin Fan; Yuanhui Liu; Lihuan Zeng; Pengyuan Chen; Chongyang Duan; Huasheng Liang; Pengcheng He
Journal:  Ann Transl Med       Date:  2021-11

10.  Impact of infection in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: insight from a multicentre observational cohort from China.

Authors:  Peng-Yuan Chen; Yuan-Hui Liu; Chong-Yang Duan; Lei Jiang; Xue-Biao Wei; Wei Guo; Ji-Yan Chen; Ning Tan; Peng-Cheng He
Journal:  BMJ Open       Date:  2020-09-14       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.